Defining imaging biomarker cut points for brain aging and Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

http://www.wikidata.org/entity/Q38803637

about

AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals.AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure.Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.1H-MRS metabolites and rate of β-amyloid accumulation on serial PET in clinically normal adults.Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.Prevalence and Natural History of Superficial Siderosis: A Population-Based Study.Age, vascular health, and Alzheimer disease biomarkers in an elderly sample.Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers.Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau.Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum.Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer's Disease.Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study.[18 F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease.Tau-negative amnestic dementia masquerading as Alzheimer disease dementia.Joint associations of β-amyloidosis and cortical thickness with cognition.Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.Revolution of Alzheimer Precision Neurology Passageway of Systems Biology and Neurophysiology.Longitudinal tau PET in ageing and Alzheimer's disease.NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.The personalized Alzheimer's disease cortical thickness index predicts likely pathology and clinical progression in mild cognitive impairment.Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants.How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture Modeling and prediction of clinical symptom trajectories in Alzheimer's disease using longitudinal data MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study

P2860

Q37633577-3671C295-7368-4235-A262-047513E18E30 Q38601321-DE2CE3C5-F010-46E8-A36D-A9379AB71EF6 Q38653494-8895F31F-5B06-489A-B529-98A42DBF5486 Q38739937-A9848723-1693-42C5-B096-B871742C5969 Q38812890-8E41FD8B-9C16-4B2B-96DB-7080E833275A Q41600997-31623070-43E3-48F0-90EF-85E6E8766F1D Q42665050-17CBFD31-FB68-442F-A1FB-398E844E58DA Q47279644-BD5165D1-895F-4266-8838-17A0B1EF1687 Q47330246-1B36206E-530A-41A3-A997-91B9037524A2 Q47602999-A9393EC1-CCC2-4639-8F47-DAF802ACF834 Q47653348-F8B2CB41-40C8-4A9C-BC44-0C7A8A731F40 Q47655041-23DF93AF-FC7B-41C9-9DC7-482843516560 Q47658947-23EEE11B-A9B4-485C-80AB-83AC6AB00C49 Q47739900-CAD82E17-E5C3-4630-9190-1324314CA8E0 Q47987344-6F96493F-B61C-467E-AB1D-2A794863A19F Q48020440-BA81C85B-ED97-408A-94CA-7B8933371E3D Q48219698-99CF7F39-8A39-4CDF-AF21-566BEF451D20 Q48261458-9752F6F8-27AF-45EF-B459-8D041E778D9C Q50042853-E6CC5D89-FD23-46F2-90C7-625FF462994B Q50422287-67EB8F6A-4C43-4613-B4E4-CF0E84612807 Q50584813-06026FA1-E38D-4FDF-81C8-CE2BD257C2B3 Q51760905-E98F7DF8-4C3E-41A4-A49E-3B8238CF5BE6 Q51763159-442C9EA2-9B4A-49BB-85A2-78A2709A00BD Q52589491-9EF8EE4D-9FDB-48E7-B75F-74E8029F4A77 Q53396875-F9EDEF0C-7D91-4348-83E8-D3F01B17BBFB Q53397663-48F1F47A-FA31-4996-906D-0A6B669E3ACB Q55231373-BE657620-36F1-4001-A079-8903FA7DD8CA Q55311648-42262B9D-0DDA-47A9-89BE-DA7257A949FA Q58697674-16E02FED-2E35-44D2-9F0C-E605B6EC3748 Q58739168-1BCE2EF5-58DC-4E1B-AEF3-53C262DB6341 Q59128613-1B008099-C469-429D-8ACB-8C1712B3F7E5

P2860

Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

http://www.wikidata.org/entity/Q38803637

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

@en

type

label

Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

@en

prefLabel

Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

@en

P1433

Q38803637-BD52DDE7-9214-41CA-BB90-A6B79057913A

P1476

Q38803637-6AF1848E-617E-4648-A48E-DE836170B24C

P2093

Q38803637-1FD22CC4-F631-4CC3-A708-F963AE8C8736

Q38803637-241942A2-7CF0-40FE-9073-BCE808ADA991

Q38803637-33367FBC-CAD3-4F43-80BD-D0AB10965A2E

Q38803637-3F527905-5209-4B18-9238-EAE4F727F83D

Q38803637-4CAD5AD0-7E43-4211-8B67-827B17A3EF64

Q38803637-4D4833D5-6810-4168-B66A-21475B3D05E6

Q38803637-524AD77F-6786-4B45-9D2A-6713888D0BDE

Q38803637-8E837C95-F541-4148-A412-051537E01167

Q38803637-CED7EC5D-FED9-4E91-B93E-73142C6B2D54

Q38803637-D9ECBFFB-0EBC-44D4-AC45-050D390A05BD

P2860

Q38803637-0061514B-BD9C-42A0-85BD-2B57C652F265

Q38803637-06DE429B-7A7E-4BFF-9F78-EC689F7AB681

Q38803637-080D0062-EA89-4AFF-808C-D788E2D8F155

Q38803637-09A9B15C-8B75-494C-8221-4AE0A6625EDD

Q38803637-0CCBBBE4-80CF-4309-8279-E80157179D3E

Q38803637-2034D36C-3595-4B95-9C93-B62C060BB9E7

Q38803637-2D7DE5D1-D9DE-403F-B535-5C6C380BB5B2

Q38803637-362BE8AD-79EA-4F95-8585-885D9AF1EB4E

Q38803637-36384001-0302-4539-80DD-B78A1FE6CE01

Q38803637-380FAB6A-6FEE-4142-A8CF-1D8F2D090390

P304

Q38803637-1140D204-6378-490C-A16D-7B3026BF0F39

P31

Q38803637-E52589F2-7C79-4102-8D87-31E0FFB2423C

P356

Q38803637-868B53B7-8613-448F-A58F-78D38F1655B0

P433

Q38803637-1051F27C-7D1B-4CD4-8D99-2132BF070F6E

P478

Q38803637-024FD0E8-5BE0-416A-95D4-B552E9CC74C9

P50

Q38803637-1669CE12-9346-4218-BE0E-0B387F455101

Q38803637-6ECEC851-FA23-47B6-BC74-5CBC739C5D0E

Q38803637-7E7DFA0B-FF82-4BB1-BAED-B25BFD10223E

Q38803637-F48FCFF2-C804-451A-9FEF-596504DC5BB3

P577

Q38803637-47E9D713-85F0-43D5-8BB5-08AA764562AB

P698

Q38803637-69C5B6DE-1D74-40E8-B2B5-9EA8E218320A

P921

Q38803637-76807CD5-8400-48E4-8F02-BD971FB05A23

Q38803637-8238D69E-4D7D-4A7D-9446-683FE45513A9

P932

Q38803637-6FA5BA36-8E3B-4957-803A-0218FB3F493A

P356

J.JALZ.2016.08.005

P1433

Alzheimer's and Dementia

P1476

Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

@en

P2093

David T Jones

http://www.w3.org/2001/XMLSchema#string

Denise A Reyes

http://www.w3.org/2001/XMLSchema#string

Heather J Wiste

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Gunter

http://www.w3.org/2001/XMLSchema#string

Mary M Machulda

http://www.w3.org/2001/XMLSchema#string

Matthew L Senjem

http://www.w3.org/2001/XMLSchema#string

Michelle M Mielke

http://www.w3.org/2001/XMLSchema#string

Prashanthi Vemuri

http://www.w3.org/2001/XMLSchema#string

Rosebud O Roberts

http://www.w3.org/2001/XMLSchema#string

Stephen D Weigand

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation

Neuropathological stageing of Alzheimer-related changes

Tau imaging: early progress and future directions

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The evolution of the reference value concept.

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

P304

205-216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JALZ.2016.08.005

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Ronald C. Petersen

David S Knopman

P577

2016-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27697430

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

5344738

http://www.w3.org/2001/XMLSchema#string